Sputum ACE2, TMPRSS2 and FURIN gene expression in severe neutrophilic asthma

Published date: 7 January 2021

Additional Information: Funding Information: Dr Djukanovic reports receiving fees for lectures at symposia organised by Novartis, AstraZeneca and TEVA, consultation for TEVA and Novartis as member of advisory boards, and participation in a scientific discussion about asthma organised by GlaxoSmithKline. He is a co-founder and current consultant, and has shares in Synairgen, a University of Southampton spin out company. Dr. Sterk has nothing to disclose. Dr. Sterk reports grants from public–private funding by the Innovative Medicines Initiative (IMI) covered by the European Union (EU) and the European Federation of Pharmaceutical Industries and Associations (EFPIA), during the conduct of the study. Dr Chung has received honoraria for participating in Advisory Board meetings of GSK, AZ, Roche, Novartis, Merck, BI, TEVA and Shionogi regarding treatments for asthma, chronic obstructive pulmonary disease and chronic cough and has also been renumerated for speaking engagements. Dr. Dahlén reports personal fees from AZ, Cayman Chemical, GSK, Novartis, Sanofi, Regeneron, TEVA, outside the submitted work. Mr Versi, Dr Kermani, Dr Song, Mr Badi, Dr Guo, Dr Sun, Dr Bhavsar, Dr Howarth and Dr Adcock have nothing to disclose. Funding Information: U-BIOPRED was supported by an Innovative Medicines Initiative Joint Undertaking (No.115010), resources from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in-kind contribution ( www.imi.europa.eu ). We thank the U-BIOPRED Project team for their contribution. Funding Information: We acknowledge the important contribution of Dr Alan Lunt who sadly passed away on 1st June 2020 and we dedicate this work in his memory. U-BIOPRED Consortium members: Uruj Hoda and Christos Rossios, Airways Disease, National Heart & Lung Institute, Imperial College London, UK & Biomedical Research Unit, Biomedical Research Unit, Royal Brompton & Harefield NHS Trust, London, UK; Elisabeth Bel, Faculty of Medicine, University of Amsterdam, Amsterdam, Netherlands; Navin Rao, Janssen Research and Development, High Wycombe, Buckinghamshire, United Kingdom; David Myles, Respiratory Therapy Area Unit, GlaxoSmithKline, Stockley Park, UK; Chris Compton, Discovery Medicine, GlaxoSmithKline, Stockley Park, UK; Marleen Van Geest, AstraZeneca R&D Molndal, Sweden; Peter Howarth & Graham Roberts, Faculty of Medicine, Southampton University, Southampton, UK and NIHR Southampton Respiratory Biomedical Research Unit, University Hospital Southampton, Southampton, UK; Diane Lefaudeux, European Institute for Systems Biology and Medicine, CNRS-ENS-UCBL, Universit? de Lyon, France; Bertrand De Meulder, European Institute for Systems Biology and Medicine, CNRS-ENS-UCBL, Universit? de Lyon, France; Aruna T Bansal, Acclarogen Ltd, St John's Innovation Centre, Cambridge, CB4 0WS, UK; Richard Knowles, Knowles Consulting, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage SG1 2FX, UK; Damijn Erzen, Boehringer Ingelheim Pharma, Germany; Scott Wagers, BioSci Consulting, BioSci Consulting, Maasmechelen, Belgium; Norbert Krug, Immunology, Allergology and Clinical Inhalation, Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany; Tim Higenbottam, Corporate Clinical Development, Chiesi Pharmaceutics Ltd, Cheadle, UK. Current address: Allergy Therapeutics, West Sussex, UK; John Matthews, Genentech Inc, 1 DNA Drive, South San Francisco, CA 94080-4990, USA; Veit Erpenbeek, Translational Medicine?Respiratory Profiling, Novartis Institutes for BioMedical Research, Basel, Switzerland; Leon Carayannopoulos, Merck Inc. Kenilworth, New Jersey, USA; Amanda Roberts, UBIOPRED Patient Input Platform, ELF, Sheffield, UK; David Supple, UBIOPRED Patient Input Platform, ELF, Sheffield, UK; Pim deBoer, UBIOPRED Patient Input Platform, ELF, Sheffield, UK; Massimo Caruso, Department of Clinical and Experimental Medicine Hospital University, University of Catania, Italy; Pascal Chanez, D?partement des Maladies Respiratoires, Laboratoire d'immunologie, Aix Marseille Universit? Marseille, France; Sven-Erik Dahlen, The Centre for Allergy Research, The Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden; Ildik? Horv?th, Department of Pulmonology, Semmelweis University, Budapest, Hungary; Nobert Krug, Fraunhofer Institute for Toxicology and Experimental Medicine Hannover, Germany; Jacek Musial, Dept. of Medicine, Jagiellonian University Medical College, Krakow, Poland; Thomas Sandstr?m, Dept of Medicine, Respiratory and Allergy unit, University Hospital, SE 901 85 Ume?, Sweden Publisher Copyright: © 2021, The Author(s). Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

Related URLs:

• http://www.scopus.com/inward/r...D=8YFLogxK

Keywords: ACE2, FURIN, Neutrophil, Severe asthma, TMPRSS2

Local EPrints ID: 452173

URI: http://eprints.soton.ac.uk/id/eprint/452173

DOI: doi:10.1186/s12931-020-01605-8

ISSN: 1465-9921

PURE UUID: a803b26e-5c26-4e7c-8e10-606bdc054340

ORCID for Ratko Djukanovic: orcid.org/0000-0001-6039-5612

ORCID for Graham Roberts: orcid.org/0000-0003-2252-1248

Date deposited: 26 Nov 2021 17:34

Last modified: 18 Mar 2024 03:01